| |
Tuesday, June 24, 2025 | 1pm ET / 11am PT Join us for this one hour deep dive with a panel of experts and industry leaders to gain valuable insights and guidance on diagnostic and precision medicine testing. Register now.
|
|
Today’s Big NewsJun 16, 2025 |
|
Wednesday June 25, 2025 | 11am ET / 8am PT In this webinar, experts reveal how structured terminology and Real-World Data normalization are transforming patient identification and feasibility — slashing screen failure rates, accelerating site selection, and finally delivering measurable ROI on data spend. Register now.
|
|
| By Fraiser Kansteiner,Zoey Becker,Eric Sagonowsky,Angus Liu,Kevin Dunleavy The pay packages handed out for last year’s work seem to further cement a new status quo in the realm of CEO compensation, as several recently appointed pharma leaders settle into their roles and companies establish their market positions heading into the second half of the decade. |
|
|
|
By Angus Liu A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy gene therapy’s safety profile. |
By James Waldron KalVista Pharmaceuticals has become the latest biotech to face delays to the FDA’s decision-making, as the agency blames a “heavy workload” for pushing back a PDUFA date. |
By Conor Hale Her $305 million offer topped the previous frontrunner, Regeneron, which bid $256 million last month and planned to incorporate the DNA company’s assets in its R&D. |
|
Tuesday, June 26, 2025 | 2:30pm ET / 11:30am PT Too many with treatment-resistant depression go undiagnosed and untreated. Join this webinar to see how AI and Real-World Data can transform detection, access, and outcomes in mental health. Register now.
|
|
By Nick Paul Taylor Biogen has emerged as a front-runner at the Cannes Lions International Festival of Creativity, snagging four spots on the Pharma shortlist for its work on Friedreich’s ataxia. But the biotech was absent from the Health & Wellness category, where Bristol Myers Squibb and Novartis led pharma representation. |
By Kevin Dunleavy Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, for $561 million up front, with the hope that it can help transform a newly launched treatment for postpartum depression into the indication's standard of care. |
By Nick Paul Taylor Gilead is laying off 36 people as part of the rethink that saw it scrap plans to expand a biologics facility in California. |
By Nick Paul Taylor Eli Lilly has shared phase 1 data on amylin analog eloralintide, impressing analysts with results that point to the potential for the drug candidate to form part of a market-leading Zepbound combination. |
By James Waldron D&D Pharmatech tested a once-weekly regimen of its dual GLP-1/glucagon receptor agonist DD01 in 67 overweight or obese patients with MASH. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we unpack Fierce Medtech's Fierce 15 and spotlight startups reimagining healthcare. |
|
|---|
|
|
|
Patients need innovative treatments to treat diseases and save lives, but today’s biopharmaceutical development and manufacturing environment presents multiple challenges for biopharma companies. Access this valuable resource for key insights on navigating the complex road to market, including quality standards, regulatory requirements, supply-chain disruptions, and more.
|
|
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
